Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Yearly Results
The yearly results for Mankind Pharma Limited (NSE:MANKIND) were released last week, making it a good time to revisit its performance. Mankind Pharma reported ₹143b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of ₹46.28 beat expectations, being 3.5% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Taking into account the latest results, the most recent consensus for Mankind Pharma from 20 analysts is for revenues of ₹159.9b in 2027. If met, it would imply a solid 12% increase on its revenue over the past 12 months. Per-share earnings are expected to bounce 23% to ₹57.11. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹159.9b and earnings per share (EPS) of ₹57.12 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
Check out our latest analysis for Mankind Pharma
It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹2,669. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Mankind Pharma analyst has a price target of ₹3,100 per share, while the most pessimistic values it at ₹2,057. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Mankind Pharma's revenue growth is expected to slow, with the forecast 12% annualised growth rate until the end of 2027 being well below the historical 16% p.a. growth over the last five years. Compare this to the 182 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 11% per year. So it's pretty clear that, while Mankind Pharma's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target held steady at ₹2,669, with the latest estimates not enough to have an impact on their price targets.
With that in mind, we wouldn't be too quick to come to a conclusion on Mankind Pharma. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Mankind Pharma going out to 2029, and you can see them free on our platform here..
You can also view our analysis of Mankind Pharma's balance sheet, and whether we think Mankind Pharma is carrying too much debt, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.